The effects of peroxisome proliferators on global lipid homeostasis and the possible significance of these effects to other responses to these xenobiotics: An hypothesis

Annals of the New York Academy of Sciences

Volumn 973, Issue , 2002, Pages 17-25

  Xie, Yi ^a   Yang, Qian ^a   DePierre, Joseph W ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Caveolae; Cholesterol; HDL; Hypolipidemic; LDL; Peroxisome proliferator; Signal

Indexed keywords

APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STATIN; XENOBIOTIC AGENT;

ADIPOSE TISSUE; ATROPHY; CAVEOLA; CELL MEMBRANE; CONFERENCE PAPER; DRUG EFFECT; HOMEOSTASIS; HYPOLIPEMIA; LIPID METABOLISM; LIVER CELL; LIVER HYPERTROPHY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SPLEEN; THYMUS;

EID: 0036962460     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04600.x     Document Type: Conference Paper

References (51)

1. OLIVER, M.F. 1963. Further observation on the effects of atromid and of ethyl chlorophenoxyisobutyrate on serum lipid levels. J. Atheroscler. Res. 3: 427-444.
2. PAGET, G.E. 1963. Experimental studies of the toxicity of atromid with particular reference to fine structural changes in the livers of rodents. J. Atheroscler Res. 3: 729-736.
3. GONZALEZ, F.J., J.M. PETERS & R.C. CATTLEY. 1998. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. J. Natl. Cancer Inst. 90: 1702-1709.
4. CATTLEY, R.C., J. DELUCA, C. ELCOMBE, et al. 1998. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul. Toxicol. Pharmacol. 27: 47-60.
5. GELMAN, L., J.C. FRUCHART & J. AUWERX. 1999. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell. Mol. Life Sci. 55: 932-943.
6. REDDY, J.K., D.L. AZARNOFF & C.E. HIGNITE. 1980. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 283: 397-398.
7. CORTON, J.C., S.P. ANDERSON & A. STAUBER. 2000. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu. Rev. Pharmacol. Toxicol. 40: 491-518.
8. VAN DEN BOSCH, H., R.B. SCHUTGENS, R.J. WANDERS & J.M. TAGER. 1992. Biochemistry of peroxisomes. Annu Rev Biochem 61: 157-197.
9. GUERRE-MILLO, M., P. GERVOIS, E. RASPE, et al. 2000. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275: 16638-16642.
10. XIE, Y., Q. YANG, B.D. NELSON & J.W. DEPIERRE. 2002. Characterization of the adipose tissue atrophy induced by peroxisome proliferators in mice. Lipids 37: 139-146.
11. YANG, Q., Y. XIE & J.W. DEPIERRE. 2000. Effects of peroxisome proliferators on the thymus and spleen of mice. Clin. Exp. Immunol. 122: 219-226.
12. YANG, Q., Y. XIE, A.M. ERIKSSON, et al. 2001. Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluoroctanoic acid in mice. Biochem. Pharmacol. 62: 1133-1140.
13. YANG, Q., M. ABEDI-VALUGERDI, Y. XIE, et al. 2002. Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. Int. Immunopharmacol. 2: 389-397.
14. YANG, Q., Y. XIE, S.E.H. ALEXSON, et al. 2002. Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice. Biochem. Pharmacol. 63: 1893-1900.
15. MALMENDIER, C.L., J.F. LONTIE, C. DELCROIX, et al. 1989. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis 77: 139-149.
16. STAELS, B., N. VU-DAC, V.A. KOSYKH, et al. 1995. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J. Clin. Invest. 95: 705-712.
17. AUWERX, J., K. SCHOONJANS, J.C. FRUCHART & B. STAELS. 1996. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 124 (Suppl.): S29-37.
18. OKOCHI, E., T. NISHIMAKI-MOGAMI, K. SUZUKI & A. TAKAHASHI. 1999. Perfluorooctanoic acid, a peroxisome-proliferating hypolipidemic agent, dissociates apolipoprotein B48 from lipoprotein particles and decreases secretion of very low density lipoproteins by cultured rat hepatocytes. Biochim. Biophys. Acta 1437: 393-401.
19. NISHIMAKI-MOGAMI, T., K. SUZUKI, E. OKOCHI & A. TAKAHASHI. 1996. Bezafibrate and clofibric acid are novel inhibitors of phosphatidylcholine synthesis via the methylation of phosphatidylethanolamine. Biochim. Biophys. ACTA 1304: 11-20.
20. NISHIMAKI-MOGAMI, T., K. SUZUKI & A. TAKAHASHI. 1996. The role of phosphatidylethanolamine methylation in the secretion of very low density lipoproteins by cultured rat hepatocytes: rapid inhibition of phosphatidylethanolamine methylation by bezafibrate increases the density of apolipoprotein B48-containing lipoproteins. Biochim. Biophys. ACTA 1304: 21-31.
21. LEE, S.S., T. PINEAU, J. DRAGO, et al. 1995. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15: 3012-3022.
22. DEPIERRE, J.W., A.K. SOHLENIUS, Y. CAI, et al. 1995. Peroxisome proliferation in response to xenobiotics. Biochem. Soc. Trans. 23: 425-429.
23. BERTHOU, L., N. DUVERGER, F. EMMANUEL, et al. 1996. Opposite regulation of human versus mouse apolipoprotein A-1 by fibrates in human apolipoprotein A-I transgenic mice. J. Clin. Invest. 97: 2408-2416.
24. BERTHOU, L., R. SALADIN, P. YAQOOB, et al. 1995. Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II, and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. Eur. J. Biochem. 232: 179-187.
25. CHINETTI, G., S. LESTAVEL, V. BOCHER, et al. 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7: 53-58.
26. FIELDING C.J. & P.E. FIELDING. 1995. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36: 211-228.
27. YOKOYAMA, S. 1998. Apolipoprotein-mediated cellular cholesterol efflux. Biochim. Biophys. Acta 1392: 1-15.
28. YE, J.M., P.J. DOYLE, M.A. IGLESIAS, et al. 2001. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat fed rats: comparison with PPAR-gamma activation. Diabetes 50: 411-417.
29. POPP-SNIJDERS, C., J.A. SCHOUTEN, R.J. HEINE, et al. 1987. Dietary supplementation of omega-3 polyunsaturated fatty acids improves insulin sensitivity in non-insulin-dependent diabetes. Diabetes Res. 4: 141-147.
30. GRAF, G.A., S.V. MATVEEV & E.J. SMART. 1999. Class B scavenger receptors, caveolae, and cholesterol homeostasis. Trends Cardiovasc. Med. 9: 221-225.
31. RUDERMAN, N.B., A.K. SAHA, D. VAVVAS & L.A. WITTERS. 1999. Malonyl-CoA, fuel sensing, and insulin resistance. Am. J. Physiol. 276: E1-E18.
32. INCARDONA, J.P. & S. EATON. 2000. Cholesterol in signal transduction. Curr. Opin. Cell. Biol. 12: 193-203.
33. PARPAL, S., M. KARLSSON, H. THORN & P. STRALFORS. 2001. Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control. J. Biol. Chem. 276: 9670-9678.
34. PEDERSON, T.M., D.L. KRAMER & C.M. RONDINONE. 2001. Serine/threonine phosphorylation of 1RS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. Diabetes 50: 24-31.
35. WAHLSTROM, H.E., R. AKIMOTO, D. ENDRES, et al. 1992. Recovery and hypersecretion of insulin and reversal of insulin resistance after withdrawal of short-term cyclosporine treatment. Transplantation 53: 1190-1195.
36. UITTENBOGAARD, A., Y. YING & E.J. SMART. 1998. Characterization of a cytosolic heatshock protein-caveolin chaperone complex. Involvement in cholesterol trafficking. J. Biol. Chem. 273: 6525-6532.
37. LALWANI, N.D., M.K. REDDY, S.A. QURESHI & J.K. REDDY. 1981. Development of hepatocellular carcinomas and increased peroxisomal fatty acid beta-oxidation in rats fed [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (Wy-14,643) in the semipurified diet. Carcinogenesis 2: 645-650.
38. LATRUFFE, N., M. CHERKAOUI-MALKI, V. NICOLAS-FRANCES, et al. 2001. Peroxisome-proliferator-activated receptors as physiological sensors of fatty acid metabolism: molecular regulation in peroxisomes. Biochem. Soc. Trans. 29: 305-309.
39. PIETERS, M.N., D. SCHOUTEN, H.F. BAKKEREN, et al. 1991. Selective uptake of cholesteryl esters from apolipoprotein-E-free high-density lipoproteins by rat parenchymal cells in vivo is efficiently coupled to bile acid synthesis. Biochem. J. 280: 359-365.
40. VAN DIJK, M.C., M. PIETERS & T.J. VAN BERKEL. 1993. Kinetics of biliary secretion of chylomicron remnant cholesterol (esters) in the rat. Eur. J. Biochem. 211: 781-787.
41. LI, Y., L.K. LEUNG, H.P. GLAUERT & B.T. SPEAR. 1996. Treatment of rats with the peroxisome proliferator ciprofibrate results in increased liver NF-kappaB activity. Carcinogenesis 17: 2305-2309.
42. LI, Y., H.P. GLAUERT & B.T. SPEAR. 2000. Activation of nuclear factor-kappaB by the peroxisome proliferator ciprofibrate in H4IIEC3 rat hepatoma cells and its inhibition by the antioxidants N-acetylcysteine and vitamin E. Biochem. Pharmacol. 59: 427-434.
43. ROKOS, C.L. & B.J. LEDWITH. 1997. Peroxisome proliferators activate extracellular signal-regulated kinases in immortalized mouse liver cells. J. Biol. Chem. 272: 13452-13457.
44. MOUNHO, B.J. & B.D. THRALL. 1999. The extracellular signal-regulated kinase pathway contributes to mitogenic and antiapoptotic effects of peroxisome proliferators in vitro. Toxicol. Appl. Pharmacol. 159: 125-133.
45. KUDOLO, G.B., P. BRESSLER & R.A. DEFRONZO. 1997. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment. J. Lipid Mediat. Cell Signal. 17: 97-113.
46. GOTTO, A.M. & J.A. FARMER. 2001. Pleiotropic effects of statins: do they matter? Curr. Opin. Lipidol. 12: 391-394.
47. LEVY, R., R.E. OSTLUND, G. SCHONFELD, et al. 1992. Cholesteryl ester storage disease: complex molecular effects of chronic lovastatin therapy. J. Lipid Res. 33: 1005-1015.
48. LAUFS, U., D. MARRA, K. NODE & J.K. LIAO. 1999: 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J. Biol. Chem. 274: 21926-21931.
49. DENOYELLE, C., M. VASSE, M. KORNER, et al. 2001. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22: 1139-1148.
50. NEMETH, P.M., O.E. HITCHINS, L. SOLANKI & T.G. COLE. 1986. Fluorometric procedures for measuring triglyceride concentrations in small amounts of tissue and plasma. J. Lipid Res. 27: 447-452.
51. BIEBER, L.L., T. ABRAHAM & T. HELMRATH. 1972. A rapid spectrophotometric assay for carnitine palmitoyltransferase. Anal. Biochem. 50: 509-518.